類澱粉沉積症治療市場規模、佔有率和成長分析（按類型、最終用途和地區分類）—產業預測（2026-2033 年）

預計到 2024 年，全球類澱粉沉積症治療市場規模將達到 63.2 億美元，到 2025 年將達到 68 億美元，到 2033 年將達到 122.1 億美元，預測期（2026-2033 年）的複合年成長率為 7.6%。

類澱粉沉積症治療市場正經歷顯著擴張，這主要得益於人們對這種罕見疾病的認知不斷提高以及診斷能力的增強。澱粉樣變性是一種由異常蛋白質沉積引起的罕見疾病，會導致器官功能障礙。推動市場成長的關鍵因素包括治療方案的進步，例如化療、幹細胞移植以及創新標靶治療，如單株抗體和小分子抑制劑，這些療法在阻止或逆轉疾病進展方面展現出巨大潛力。製藥公司不斷增加的研發投入也促進了市場競爭，推動治療方案的拓展。然而，挑戰依然存在，例如治療費用的可負擔性以及早期診斷對改善患者預後的重要性。持續的研究投入和更有效治療方法的開發有望維持這一市場成長趨勢。

類澱粉沉積症治療的促進因素

推動類澱粉沉積症治療市場發展的主要因素是該疾病發生率的不斷上升，其中包括AL型類澱粉沉積症和ATTR型類澱粉沉積症。公眾意識的提高和診斷技術的進步使得更多病例得以確診。診斷病例的激增導致需要有效治療方案的患者人數增加。隨著類澱粉沉積症的認知不斷加深，以及需要治療的患者人數不斷成長，預計該市場將顯著成長，從而滿足患者對創新治療方法和綜合管理方案的迫切需求。

限制類澱粉沉積症治療市場的因素

由於有效治療方案有限，類澱粉沉積症治療市場面臨嚴峻挑戰。儘管研發取得了進展，但現有治療方法仍無法為許多患者帶來滿意的療效。現有治療方法往往不足，凸顯了開發更具創新性和高效性的治療方案的迫切需求。因此，尋求更有效的治療方法仍然是市場的焦點，患者和醫療服務提供者都希望在應對這種複雜且棘手的疾病時獲得更好的療效。這項限制因素也凸顯了該領域持續研發的迫切性。

類澱粉沉積症治療市場趨勢

在標靶治療的推動下，類澱粉沉積症治療市場目前正經歷顯著的進展。該領域的研究和開發日益集中於創新單株抗體和小分子化合物，旨在抑制澱粉樣蛋白的生成和沈積，而澱粉樣蛋白正是疾病進展的核心。目前正在進行多項臨床試驗，以探索這些前景廣闊的新治療方法的安全性和有效性，這令人對其改善患者預後的潛力充滿信心。這一趨勢標誌著醫療策略正朝著更個人化的方向發展，有望提高治療效果，並更好地管理這種複雜的疾病。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球類澱粉沉積症治療市場規模（按類型分類）、複合年成長率（2026-2033 年）

• 藥物治療
  • 化療
  • 標靶治療
  • 抗血管新生療法
  • 單株抗體
  • 蛋白酶體抑制劑
• 外科手術
  • 骨髓移植/幹細胞移植
  • 器官移植

全球類澱粉沉積症治療市場規模（依最終用途分類）、複合年成長率（2026-2033 年）

• 醫院和診所
• 門診手術中心
• 居家醫療環境
• 其他

全球類澱粉沉積症治療市場規模，複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Alnylam Pharmaceuticals（United States）
• Ionis Pharmaceuticals（United States）
• Intellia Therapeutics（United States）
• Genmab（Denmark）
• Pfizer（United States）
• BridgeBio Pharma（United States）
• Eidos Therapeutics（United States）
• Prothena Corporation（United States）
• Alexion Pharmaceuticals（United States）
• SOM Biotech（Spain）
• Neurimmune（Switzerland）
• Corino Therapeutics（United States）
• Proclara Biosciences（United States）
• Arcturus Therapeutics（United States）
• Dicerna Pharmaceuticals（United States）
• GlaxoSmithKline（United Kingdom）
• Johnson & Johnson（United States）
• Novartis（Switzerland）
• Roche（Switzerland）

結論與建議

Amyloidosis Treatment Market size was valued at USD 6.32 Billion in 2024 and is poised to grow from USD 6.8 Billion in 2025 to USD 12.21 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The amyloidosis treatment market is experiencing notable expansion, driven by heightened awareness and improved diagnostic capabilities for this rare disease, where abnormal protein deposits lead to organ dysfunction. Key factors propelling market growth include advancements in therapeutic options, such as chemotherapy, stem cell transplants, and innovative targeted therapies like monoclonal antibodies and small molecule inhibitors that demonstrate potential in halting or reversing disease progression. Increased investment from pharmaceutical companies in research and development is fostering a competitive environment, with a focus on expanding treatment alternatives. However, challenges persist, particularly in terms of treatment affordability and the critical need for early diagnosis to enhance patient outcomes. Continued research efforts and the development of more effective therapies are poised to sustain this market's growth trend.

Top-down and bottom-up approaches were used to estimate and validate the size of the Amyloidosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Amyloidosis Treatment Market Segments Analysis

Global Amyloidosis Treatment Market is segmented by Type, End-use and region. Based on Type, the market is segmented into Medication and Surgery. Based on End-use, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Amyloidosis Treatment Market

A notable factor propelling the amyloidosis treatment market is the increasing incidence of the disease, which encompasses both AL amyloidosis and ATTR amyloidosis. With enhanced awareness and advancements in diagnostic techniques, a higher number of cases are being identified. This surge in diagnosis contributes to a growing patient population requiring effective treatment options. As the understanding of amyloidosis expands and more individuals are recognized as needing care, the market is positioned for significant growth, addressing the essential need for innovative therapies and comprehensive management solutions for those affected by this condition.

Restraints in the Amyloidosis Treatment Market

The amyloidosis treatment market faces significant challenges due to the limited availability of effective therapeutic options. Despite progress in research and drug development, current treatments do not yield satisfactory results for many patients affected by this condition. The existing therapies often fall short in their effectiveness, highlighting a critical need for the development of more innovative and efficient treatment solutions. Consequently, the quest for improved therapies remains a central concern within the market, as patients and healthcare providers seek better outcomes in managing this complex and challenging disease. This limitation underscores the urgency for continued research and advancement in the field.

Market Trends of the Amyloidosis Treatment Market

The amyloidosis treatment market is currently experiencing significant advancements driven by a strong focus on targeted therapies. Research and development in this sector are increasingly centered on innovative monoclonal antibodies and small molecules aimed at inhibiting the production or deposition of amyloid proteins, which are central to disease progression. With numerous clinical trials exploring the safety and efficacy of these promising novel therapies, there is a growing optimism regarding their potential to transform patient outcomes. This trend highlights a shift towards more personalized medicine strategies, enhancing treatment efficacy, and possibly leading to better management of this complex disease.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Amyloidosis Treatment Market Size by Type & CAGR (2026-2033)

• Market Overview
• Medication
  • Chemotherapy
  • Targeted therapy
  • Anti-Angiogenesis Therapy
  • Monoclonal Antibodies
  • Proteasome Inhibitors
• Surgery
  • Bone Marrow Transplantation/Stem Cell Transplantation
  • Organ Transplantation

Global Amyloidosis Treatment Market Size by End-use & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Global Amyloidosis Treatment Market Size & CAGR (2026-2033)

• North America (Type, End-use)
  • US
  • Canada
• Europe (Type, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eidos Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOM Biotech (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurimmune (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corino Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proclara Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcturus Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations